| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.43B | 2.31B | 2.30B | 1.92B | 1.73B | 1.69B |
| Gross Profit | 818.42M | 771.09M | 762.63M | 609.81M | 619.71M | 605.44M |
| EBITDA | 537.09M | 563.31M | 589.05M | 466.57M | 508.89M | 504.30M |
| Net Income | 379.55M | 404.49M | 428.40M | 318.76M | 360.80M | 347.56M |
Balance Sheet | ||||||
| Total Assets | 2.94B | 2.76B | 2.68B | 2.39B | 2.13B | 2.22B |
| Cash, Cash Equivalents and Short-Term Investments | 183.40M | 255.62M | 240.79M | 241.76M | 267.74M | 450.54M |
| Total Debt | 13.03M | 4.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 441.22M | 288.72M | 365.67M | 323.58M | 193.40M | 260.28M |
| Stockholders Equity | 2.50B | 2.47B | 2.31B | 2.07B | 1.94B | 1.96B |
Cash Flow | ||||||
| Free Cash Flow | 470.90M | 353.54M | 353.57M | 191.77M | 293.33M | 412.79M |
| Operating Cash Flow | 616.02M | 498.21M | 537.25M | 338.20M | 362.17M | 464.49M |
| Investing Cash Flow | -272.48M | -202.08M | -299.42M | -172.74M | -113.11M | 26.42M |
| Financing Cash Flow | -341.79M | -289.25M | -230.15M | -209.02M | -410.12M | -363.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $4.14B | 16.86 | 18.19% | ― | 7.94% | 34.84% | |
75 Outperform | $5.59B | 13.19 | 8.96% | 2.96% | -1.90% | -13.86% | |
74 Outperform | $8.92B | 12.12 | 31.09% | 2.64% | 0.84% | 26.17% | |
72 Outperform | $9.33B | 69.86 | 2.24% | 1.10% | 0.08% | -83.69% | |
71 Outperform | $2.81B | 9.26 | 23.16% | 0.53% | -4.03% | -39.51% | |
70 Outperform | $4.98B | 13.45 | 15.23% | 2.11% | 2.99% | -9.80% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
The recent earnings call for Gentex Corp painted a mixed picture for the company, highlighting both achievements and challenges. While there was notable growth in overall sales and improvements in gross margins, these positive aspects were counterbalanced by declines in core Gentex revenue and significant revenue drops in Europe and China. The company also faced a decrease in income from operations and net income, with international market challenges and tariffs posing significant concerns.